AVLN vs LBRX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
AVLN · Avalyn Pharma$29.15 ▲ 9.30%
LBRX · LB Pharmaceuticals$42.01 ▲ 10.29%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- AVLN -1.2%
- LBRX +32.5%
Head to head
| Metric | AVLN | LBRX |
|---|---|---|
| Price | $29.15 | $42.01 |
| Change today | ▲ 9.30% | ▲ 10.29% |
| Market cap | $1.29B | $1.36B |
| Return, 3 months | -15.7% | -8.4% |
| Return, year to date | – | +88.7% |
| Return, 1 year | – | +173.7% |
| P/E (TTM) | – | 41.4 |
| P/B | 3.2 | 3.3 |
| P/E percentile vs own 5y | 89th | 77th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | -43.3% | -959.4% |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | -25.9% | -75.0% |
| Analyst target vs. price | +93.2% | +56.8% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 60 | 58 |
| 30-day volatility | 63.5% | 62.6% |
| Max drawdown, 1 year | -40.6% | -31.3% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- LBRX is the largest of the group by market value.
- LBRX has been the calmest stock over the last 30 days.